Manoj Tyagi

Head of Bioinformatics Unit

National Institutes of Health
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (1)

Purpose: Despite promising preclinical studies, toxicities have precluded combinations of chemotherapy and DNA damage response (DDR) inhibitors. We hypothesized that tumor-targeted chemotherapy delivery might enable clinical translation of such combinations. Patients and Methods: In a phase I trial, we combined sacituzumab govitecan, antibody-drug conjugate (ADC) that delivers topoisomerase-1 inhibitor SN-38 to tumors expressing Trop-2, with ataxia telangiectasia and Rad3-related (ATR) inhibitor berzosertib. Twelve patients were enrolled across three dose levels. Results: Treatment was well tolerated, with improved safety over conventional chemotherapy-based combinations, allowing escalation to the highest dose. No dose-limiting toxicities or clinically relevant ≥ grade 4 adverse events occurred. Tumor regressions were observed in two patients with neuroendocrine prostate cancer and a patient with small cell lung cancer transformed from EGFR-mutant non-small cell lung cancer. Conclusions: ADC-based delivery of cytotoxic payloads represents a new paradigm to increase efficacy of DDR inhibitors.

Year:

2024

Collaborators (5)

Parth Anil Desai

Assistant Professor/Clinical Investigator

Fox Chase Cancer Center

UNITED STATES
View details

Christopher William Schultz

Assistant Professor

Temple University

UNITED STATES
View details

Liqiang Xi

Staff Scientist

National Institutes of Health

UNITED STATES
View details

SHUBHANK GOYAL

The University of Texas Rio Grande Valley

UNITED STATES
View details

William D Figg

Senior Investigator, Lab Chief, Associate Director

National Institutes of Health

UNITED STATES
View details